Blue­print part­ners up with a de­grad­er-fo­cused 'van­t' as part of pipeline-boost­ing cam­paign

Part of Vivek Ra­maswamy and Matt Gline’s ex­pan­sive uni­verse of “vants,” the lit­tle-known de­grad­er play Pro­teo­vant has silent­ly been chip­ping away for more than a year. Now, Blue­print Med­i­cines will take a bet on that biotech and its AI-fo­cused sis­ter firm.

Blue­print will pay $20 mil­lion up­front and a po­ten­tial $632 mil­lion in ad­di­tion­al down­stream mile­stones for two pro­tein de­grad­er pro­grams from Pro­teo­vant with the op­tion to add two more pro­grams to the slate, the part­ners said Mon­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER